Corpus overview


Overview

MeSH Disease

Human Phenotype

Diarrhea (125)

Fever (78)

Cough (75)

Fatigue (38)

Pneumonia (31)


Transmission

Seroprevalence
    displaying 41 - 50 records in total 125
    records per page




    Alarming Symptoms Leading To Severe COVID-19 Pneumonia HP: A Meta-Analysis

    Authors: Weiping Ji; Jing Zhang; Gautam Bishnu; Xudong Du; Xinxin Chen; Hui Xu; Xiaoling Guo; Zhenzhai Cai; Jun Zhang; Xian Shen

    doi:10.21203/rs.3.rs-35449/v1 Date: 2020-06-14 Source: ResearchSquare

    Background: To identify alarming symptoms that could potentially lead to severe form of COVID-19 pneumonia HP pneumonia MESHD (i.e. novel coronavirus pneumonia MESHD pneumonia HP: NCP), a disease that is now having pandemic spread.Methods: Articles from PubMed, Embase, Cochrane database and Google up to 24 February 2020 were systematically reviewed. 18 publications that had documented cases of COVID-19 pneumonia HP pneumonia MESHD were identified. The relevant data were extracted, systematically reviewed and further evaluated using meta-analysis. We define severe COVID-19 pneumonia HP pneumonia MESHD as the disease status that requires admission to the intensive care unit (ICU) and respiratory/circulatory support, which is in align with the guideline from the World Health Organization (WHO).Results: 14 studies including 1,424 patients were considered eligible and analyzed. Symptoms such as fever HP fever MESHD (89.2%), cough HP (67.2%), fatigue HP fatigue MESHD (43.6%) were quite common; but dizziness MESHD, hemoptysis HP, abdominal pain HP abdominal pain MESHD and conjunctival congestion/ conjunctivitis HP conjunctivitis MESHD were relatively rare. The incidence of dyspnea HP dyspnea MESHD was significantly higher in patients with severe than non-severe COVID-19 pneumonia HP pneumonia MESHD (42.7% vs.16.3%, p<0.0001). Similarly, fever HP fever MESHD and diarrhea HP diarrhea MESHD were also drastically more common in patients with severe form (p=0.0374 and 0.0267). Further meta-analysis using three high-quality China-based studies confirmed such findings and showed that dyspnea HP dyspnea MESHD, fever HP fever MESHD and diarrhea HP diarrhea MESHD were 3.53 (OR: 3.53, 95%CI: 1.95-6.38), 1.70 (OR: 1.70, 95%CI: 1.01-2.87), and 1.80 (OR: 1.80, 95%CI: 1.06-3.03) folds higher respectively in patients with severe COVID-19 pneumonia HP pneumonia MESHD.Conclusion: Dyspnea HP Dyspnea MESHD, fever HP and diarrhea HP diarrhea MESHD are significantly more prevalent in patients with severe COVID-19 pneumonia HP pneumonia MESHD, suggesting they are alarming symptoms that warrant close attention and timely management.

    "Analysis of the Primary Presenting Symptoms and Hematological Findings of COVID19 Patients in Bangladesh"

    Authors: Abu Taiub Mohammed Mohiuddin Chowdhury; Md Rezaul Karim; H.M.Hamidullah Mehedi; Mohammad Shahbaz; Md Wazed Chowdhury; Dan Guo; Shuixiang He

    doi:10.21203/rs.3.rs-35016/v1 Date: 2020-06-12 Source: ResearchSquare

    Background:SARS-Cov-2 infection MESHD or COVID-19 is a global pandemic. From the time of identification to till, multiple clinical symptoms and parameters have been identified by the researchers of various countries and regions regarding the diagnosis and presentations of COVID19 disease. In this manuscript, we investigated the primary symptoms and basic hematological presentations of SARS-CoV-2 infection MESHD among the Bangladeshi patients. Methodology: We have collected the disease history of mild to moderate degree of COVID19 patients; hematological MESHD and biochemical on admission reports of moderate degree COVID19 patients.  All of them were tested positive for SARS-CoV-2 by RT PCR in different institutes in Bangladesh. Results: According to this study though COVID19 patients in Bangladesh commonly presented with fever HP fever MESHD, cough HP cough MESHD, fatigue HP fatigue MESHD, shortness of breath MESHD, and sore throat, but symptoms like myalgia HP myalgia MESHD, diarrhea HP diarrhea MESHD, skin rash HP skin rash MESHD, headache HP headache MESHD, Abdominal pain HP Abdominal pain MESHD/cramp, nausea, vomiting HP nausea, vomiting MESHD vomiting MESHD, restlessness HP, and a higher temperature of >1000F have a greater presentation rate and more frequent than other published studies. CRP and Prothrombin time was found to increase in all the patients. Serum SERO ferritin, ESR, SGPT, and D-Dimer were found increased among 53.85%, 80.43, 44%, and 25% patients respectively. 17.39% of the patients had leucocytosis and neutrophilia HP. 28.26% of patients presented with lymphocytopenia MESHD. 62.52% of patients had mild erythrocytopenia. Conclusion: Despite some similarities, our study has evaluated a different expression in presenting symptoms in the case of COVID19 patients in Bangladesh. CRP, Prothrombin time, serum SERO ferritin, ESR, SGPT, D-Dimer, erythrocytopenia, and lymphocytopenia MESHD can be initial diagnostic hematological findings and assessments for prognosis COVID19 disease. Also, Gender TRANS variation has a different scenario of clinical and laboratory appearance in this region.

    Gastrointestinal symptoms and fecal nucleic acid testing of children TRANS with coronavirus disease MESHD 2019: a systematic review and meta-analysis

    Authors: Ji-Gan Wang; Hairong Cui; Huabo Tang

    doi:10.21203/rs.3.rs-34733/v1 Date: 2020-06-12 Source: ResearchSquare

    Objective: To understand the clinical manifestations and incidence of gastrointestinal symptoms of Coronavirus disease MESHD (COVID-19) in children TRANS and discuss the importance of fecal nucleic acid testing.Methods: Retrospective analysis of studies of gastrointestinal symptoms MESHD and fecal nucleic acid detection in pediatric COVID-19 since the outbreak of COVID-19, as well as prospective clinical studies and case reports to understand the clinical characteristics of gastrointestinal symptoms and feces in children TRANS. Nucleic acid detection results were also analyzed.Results: 1. The clinical manifestations of gastrointestinal symptoms in children TRANS with COVID-19 are mostly vomiting HP vomiting MESHD and diarrhea HP diarrhea MESHD, with a total incidence rate of 21.1% (95%Cl=0.14-0.28).2.When analyzing by country (studies from China versus studies from other countries), the pooled prevalence SERO of gastrointestinal symptoms in studies from countries other than China was much lower at 18.2% (95% CI0.05 to 0.31). This is in comparison to studies from China where the prevalence SERO was higher: 23.3% (95% CI 0.153 to 0.310) .3.In Wuhan patients, the pooled prevalence SERO was much higher at 41.2% (95 % CI 0.147 to 0.678) as compared to areas outside Wuhan,China:15.1%(95 % CI 0.075 to 0.227).4.Fecal nucleic acid detection is as accurate as respiratory specimen nucleic acid detection. The positive rate of fecal nucleic acid testing in COVID-19 patients was 92.5% (25/27). In patients where nucleic acid tests of respiratory tract specimens produced negative results, a positive fecal nucleic acid test result was present in 83.3% (20/24); one week after the respiratory tract specimen was nucleic acid-negative, 54.1% (13/24) were fecal nucleic acid-positive; two weeks after the respiratory tract nucleic acid negative test, 37.5% (9/24) were fecal nucleic acid-positive. The longest interval between a negative respiratory system result and positive fecal specimen result exceeded 19 days.Conclusions and Relevance: Gastrointestinal symptoms in pediatric COVID-19 are relatively common. Attention should be paid to the detection of fecal nucleic acids in children TRANS. Fecal nucleic acid-negative status should be considered as one of the desegregation standards.

    A short therapeutic regimen based on hydroxychloroquine plus azithromycin for the treatment of COVID-19 in patients with non-severe disease. A strategy associated with a reduction in hospital admissions and complications.

    Authors: José A. Oteo; Pedro Marco; Luis Ponce de León; Alejandra Roncero; Teófilo Lobera; Valentín Lisa

    doi:10.1101/2020.06.10.20101105 Date: 2020-06-12 Source: medRxiv

    The new SARS-CoV-2 infection MESHD named COVID-19 has severely hit our Health System. At the time of writing this paper no medical therapy is officially recommended or has shown results in improving the outcomes in COVID-19 patients. With the aim of diminishing the impact in Hospital admissions and reducing the number of medical complications, we implemented a strategy based on a Hospital Home-Care Unit (HHCU) using an easy-to-use treatment based on an oral administration regimen outside the hospital with hydroxychloroquine (HCQ) plus azithromycin (AZM) for a short period of 5 days. Patients and methods: Patients [≥] 18 years old visiting the emergency room at the Hospital Universitario San Pedro de Logrono (La Rioja) between March, 31st and April, 12th diagnosed with COVID-19 with confirmed SARS-CoV-2 infection MESHD by a specific PCR, as follows: Patients with pneumonia HP pneumonia MESHD (CURB [≤] 1) who did not present severe comorbidities and had no processes that contraindicated this therapeutic regime. Olygosimptomatic patients without pneumonia HP pneumonia MESHD aged TRANS [≥] 55 years. Patients [≥] 18 years old without pneumonia HP pneumonia MESHD with significant comorbidities. We excluded patients with known allergies HP allergies MESHD to some of the antimicrobials used and patients treated with other drugs that increase the QTc MESHD or with QTc >450msc. The therapeutic regime was: HCQ 400 mg every twice in a loading dose followed by 200 mg twice for 5 days, plus AZM 500 mg on the first day followed by 250 mg daily for 5 days. A daily telephone follow-up was carried out from the hospital by the same physician. The end-points of our study were: 1.- To measure the need for hospital admission within 15 days after the start of treatment. 2.- To measure the need to be admitted to the intensive care unit (ICU) within 15 days after the start of the treatment. 3.- To describe the severity of the clinical complications developed. 4.- To measure the mortality within 30 days after starting treatment (differentiating if the cause is COVID-19 or something else). 5.-To describe the safety and adverse effects of the therapeutic regime. Results: During the 13 days studied a total of 502 patients were attended in the emergency room due to COVID-19. Forty-two were sent at home; 80 were attended by the HHCU (patients on this study) and 380 were admitted to the Hospital. In our series there were a group of 69 (85.18%) patients diagnosed with pneumonia HP pneumonia MESHD (37 males TRANS and 32 females TRANS). Most of them, 57 (82.60%) had a CURB65 score of <1 (average age TRANS 49) and 12 (17.40%) a CURB score of 1 (average age TRANS 63). Eighteen (22.50%) of the pneumonia HP pneumonia MESHD patients also had some morbidity as a risk factor. 11 patients (13.75%) without pneumonia HP pneumonia MESHD were admitted to the HHCU because comorbidities or age TRANS [≥] 55 years. Six patients with pneumonia HP pneumonia MESHD had to be hospitalized during the observation period, 3 of them because side effects and 3 because of worsening. One of these patients, with morbid obesity HP obesity MESHD and asthma HP asthma MESHD, had clinical worsening needing mechanical ventilation at ICU and developed acute distress respiratory syndrome MESHD distress respiratory HP syndrome. With the exception of the patient admitted to the ICU, the rest of the patients were discharged at home in the following 8 days (3 to 8 days). Twelve patients (15%), 11 of whom had pneumonia HP pneumonia MESHD, experienced side effects affecting mainly the digestive. In another patient a QTc interval prolongation MESHD (452 msc) was observed. In total 3 of these patients had to be admitted in the Hospital, 2 because of vomiting HP vomiting MESHD and 1 because a QTc interval lengthening. None of the patients needed to stop the HCQ or AZM and all the 80 patients finished the therapeutic strategy. From the group without pneumonia HP pneumonia MESHD only a patient developed diarrhea HP diarrhea MESHD that did not require hospitalization or stop the medication. Conclusions: Our strategy has been associated with a reduction in the burden of hospital pressure, and it seems to be successful in terms of the number of patients who have developed serious complications and / or death. None of the patients died in the studied period and only 6 have to be admitted in conventional hospitalization area.

    PROGNOSTIC VALUE OF COMORMIDITY FOR SEVERITY OF COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS STUDY

    Authors: Mobina Fathi; Kimia Vakili; Fatemeh Sayehmiri; Ashraf Mohamadkhani; Mohammadreza Hajiesmaeili; Mostafa Rezaei-Tavirani; Owrang Eilami

    doi:10.1101/2020.06.11.20128835 Date: 2020-06-12 Source: medRxiv

    Abstract: Background and Aim: With the increase in the number of COVID-19 infections, global health is facing insufficient sources; this study aimed to provide additional data regarding the clinical characteristics of patients diagnosed with COVID-19 and in particular to analyze the factors associated with disease severity, unimprovement and mortality. Methods: 82 studies were included in the present meta-analysis that all of them have been published before May 1, 2020 and were found by searching through the databases Scopus and MEDLINE. The selected papers were studied and analyzed by employing the version 14 of stata software. It should be noted that, we employed I2 statistics for testing and verifying heterogeneity. Results: 82 papers were finally chosen for this meta- analysis, including 74855 infected MESHD patients (35673 men, 31140 women). The mean age TRANS of the patients was 56.49. The results indicate the prevalence SERO of fever HP fever MESHD 79.84 (95% CI: 75.22-84.13), cough HP 59.53 (95% CI: 55.35-63.65), fatigue HP fatigue MESHD or myalgia HP myalgia MESHD 33.46 (95% CI: 28.68-38.40), dyspnea HP dyspnea MESHD 31.48 (95% CI: 25.75-37.49) and diarrhea HP diarrhea MESHD 10.71 (95% CI: 8.20-13.49). The prevalence SERO of the most common comorbidities were hypertension HP hypertension MESHD 25.10 (95% CI: 19.91-30.64), diabetes MESHD 13.48 (95% CI: 10.61-16.62), cardiovascular diseases MESHD 8.94 (95% CI: 6.99-11.10), and chronic kidney disease HP chronic kidney disease MESHD 3.27 (95% CI: 2.22-4.47). Conclusion: The results of this study are seriously needed to effectively monitor the health of people with comorbidities ( hypertension HP hypertension MESHD, diabetes MESHD, cardiovascular and cerebrovascular disease MESHD, coronary heart disease MESHD disease, and chronic kidney HP chronic kidney disease MESHD) to prevent the development of COVID-19 infection MESHD.

    Gastrointestinal symptoms and fecal nucleic acid testing of children TRANS with 2019 coronavirus disease MESHD: a systematic review and meta-analysis

    Authors: Ji-Gan Wang; Hairong Cui; Huabo Tang; Xiu-li Deng

    doi:10.21203/rs.3.rs-34733/v2 Date: 2020-06-12 Source: ResearchSquare

    In order to understand the clinical manifestations and incidence of gastrointestinal symptoms of coronavirus disease MESHD (COVID-19) in children TRANS and discuss the importance of fecal nucleic acid testing.We retrospectively analyzed studies on gastrointestinal symptoms and fecal nucleic acid detection in pediatric COVID-19 patients from January 1, 2020 to August 10, 2020, including prospective clinical studies and case reports. The results of fecal nucleic acid detection were analyzed systematically. Stata12.0 software was used for meta-analysis.The results showed that the most common gastrointestinal symptoms in children TRANS with COVID-19 were vomiting HP vomiting MESHD and diarrhea HP diarrhea MESHD, with a total incidence of 17.7% (95% Cl: 13.9%-21.5%). However, the prevalence SERO of gastrointestinal symptoms MESHD in other countries (21.1%, 95% CI: 16.5%-25.7%) was higher compared to China (12.9%, 95% CI: 8%-17.7%). In Wuhan, the pooled prevalence SERO was much higher (41.3%, 95 % CI: 3.2%-79.4%) compared to areas outside Wuhan in China (7.1%, 95 % CI: 4.0%-10.3%).The positive rate of fecal nucleic acid testing in COVID-19 children TRANS was relatively high at 85.8% (91/106). Additionally, 71.2% (52/73) were still positive for fecal nucleic acid after respiratory tract specimens turned negative. One and two weeks after the respiratory tract specimens turned nucleic acid-negative, 45.2% (33/73) and 34.2% (25/73) patients, respectively, remained fecal nucleic acid-positive. The longest interval between the respiratory tract specimens turning negative and fecal specimens turning negative exceeded 70 days.Conclusions and Relevance:Gastrointestinal symptoms in pediatric COVID-19 are relatively common. Attention should be paid to the detection of fecal nucleic acids in children TRANS. Fecal nucleic acid-negative status should be considered as one of the desegregation standards.

    Clinical characteristics of SARS-CoV-2 patients: a French cross-sectional study in primary care

    Authors: Paul Sebo; Benoit Tudrej; Julie Lourdaux; Clara Cuzin; Martin Floquet; Dagmar M Haller; Hubert Maisonneuve

    doi:10.21203/rs.3.rs-34635/v1 Date: 2020-06-11 Source: ResearchSquare

    Background: The early identification of patients suffering from SARS-CoV-2 infection MESHD in primary care is of outmost importance in the current pandemic.Aim: To gain a better understanding of the specific symptoms of SARS-CoV-2 infection MESHD in primary care.Design and setting: We conducted a cross-sectional study between March 24 and May 7, 2020, involving consecutive patients undergoing RT-PCR testing in two community-based laboratories in Lyon (France) for a suspicion of COVID-19.Methods: We examined the association between various symptoms and a positive test using univariate and multivariate logistic regression, adjusted for clustering within the laboratories.Results: Of the 1561 patients tested, 1543 agreed to participate (participation rate: 99%). Among them, 253 were positive for SARS-Cov-2 (16%). In multivariate analysis, loss of taste (OR 3.8 [95%CI 3.3-4.4], p-value<0.001), loss of smell (OR 3.0 [95%CI 1.9-4.8], p-value<0.001), muscle pain MESHD pain HP (OR 1.6 [95%CI 1.2-2.0], p-value 0.001) and dry nose (OR 1.3 [95%CI 1.1-1.6], p-value 0.01) were significantly associated with a positive result. The strength of association with taste and smell disorders was higher for symptom combinations (OR 6.5 [95%CI 3.9-10.8] for loss of taste MESHD and smell, OR 6.7 [95%CI 5.9-7.5] for loss of taste MESHD or smell). In contrast, sore throat (OR 0.6 [95%CI 0.4-0.8], p-value 0.003), stuffy nose (OR 0.7 [95%CI 0.6-0.7], p-value<0.001), diarrhea HP diarrhea MESHD (OR 0.6 [95%CI 0.5-0.6], p-value<0.001) and dyspnea HP dyspnea MESHD (OR 0.5 [95%CI 0.3-0.7], p-value<0.001) were inversely associated with a positive test.Conclusion: Our data could further facilitate targeted screening and contribute to the triage and early identification of new clusters of cases.

    Epidemiological approximation of the enteric manifestation and possible fecal-oral transmission TRANS in COVID-19: A preliminary systematic review

    Authors: Javier Pamplona, PhD; Rubén Solano, PhD; Cristina Soler, MD; Miriam Sàbat, PhD

    doi:10.21203/rs.3.rs-33873/v1 Date: 2020-06-05 Source: ResearchSquare

    Objectives: to conduct a systematic review to describe the epidemiological scientific evidence on gastrointestinal symptoms MESHD ( GIS MESHD), enteric involvement and fecal excretion of SARS-CoV-2 viral RNA and to discuss the possible fecal-oral transmission TRANS pathway of COVID-19.Methods: We have reviewed GIS MESHD, enteric involvement, and fecal test results of SARS CoV-2 from case reports and retrospective observational studies related to the digestive system published about the outbreak.Results: The prevalence SERO of GIS MESHD in patients infected with SARS CoV-2 ranges from 1.7% (1/56)-100% (10/10), GIS MESHD included diarrhea HP diarrhea MESHD 1/99(1%)-8/10(80%), nausea/vomiting HP nausea/vomiting MESHD 1/28(3.6%)-5/10 (50%), abdominal pain HP abdominal pain MESHD 2/103(1.9%)-1/3(33.3%). A total of 3% of infected MESHD patients may experience GIS MESHD in the absence of respiratory symptoms. A pooled analysis of the results showed 16.1% GIS MESHD, 8.3% diarrhea HP diarrhea MESHD and 12% nausea-vomiting HP nausea-vomiting MESHD. A higher percentage of diarrhea HP diarrhea MESHD in patients with severe disease (5.8%) than in non-severe disease (3.5%), and a more severe course in patients with GIS MESHD (22.97%) than in those without GIS MESHD (8.12%) was found. Histological studies demonstrated the presence of ACE2 receptors and the nucleocapsid of the virus in gastrointestinal. The RNA of the virus has been detected in 27-53% of patients with COVID-19 in whom respiratory and stool samples have been analyzed, and it may persist in stool for up to an average of 11.2 days after negativization of the respiratory samples.Conclusions: GIS MESHD are common in SARS CoV-2 infection MESHD at the time of patient admission, sometimes represent the only clinical manifestation. Infection of the GI MESHD tract is possible due to the presence of ACE2 receptors, and there may be viral replication with fecal elimination.

    Clinical severity and epidemiological spectrum of coronavirus disease MESHD 2019 in children TRANS – comparison with influenza

    Authors: Maria Pokorska-Śpiewak; Ewa Talarek; Jolanta Popielska; Karolina Nowicka; Agnieszka Ołdakowska; Konrad Zawadka; Barbara Kowalik-Mikołajewska; Anna Tomasik; Anna Dobrzeniecka; Marta Lipińska; Beata Krynicka-Czech; Urszula Coupland; Aleksandra Stańska-Perka; Małgorzata Ludek; Magdalena Marczyńska

    doi:10.21203/rs.3.rs-32960/v1 Date: 2020-06-01 Source: ResearchSquare

    Data on the novel coronavirus disease MESHD 2019 (COVID-19) in children TRANS are limited, and studies from Europe are scarce. We analyzed the clinical severity and epidemiologic aspects of COVID-19 in consecutive children TRANS aged TRANS 0 – 18 years, referred with a suspicion of COVID-19 between February 1, and April 15, 2020. RT-PCR on a nasopharyngeal swab was used to confirm COVID-19. 319 children TRANS met the criteria of a suspected case. COVID-19 was diagnosed in 15/319 (4.7%) patients (8 male TRANS; mean age TRANS 10.5 years). All of them had household contact TRANS with an infected relative. Five (33.3%) patients were asymptomatic TRANS. In 9/15 (60.0%) children TRANS, the course of the disease was mild, and in 1/15 (6.7%), it was moderate, with the following symptoms: fever HP fever MESHD (46.7%), cough HP (40%), diarrhea HP diarrhea MESHD (20%), vomiting HP vomiting MESHD (13.3%), rhinitis HP rhinitis MESHD (6.7%), and shortness of breath MESHD (6.7%). In the COVID-19-negative patients, other infections were confirmed TRANS infections were confirmed MESHD, including influenza in 32/319 (10%). The clinical course of COVID-19 and influenza differed significantly based on the clinical presentation. In conclusion, the clinical course of COVID-19 in children TRANS is usually mild or asymptomatic TRANS. In children TRANS suspected of having COVID-19, other infections should not be overlooked. The main risk factor for COVID-19 in children TRANS is household contact TRANS with an infected relative.

    Sociodemographic profile, clinical characteristics, anxiety HP anxiety MESHD, and depression MESHD of 74 patients infected with COVID-19: first report from Bangladesh

    Authors: Dr. Mohammad Jahid Hasan; Dr. Md. Abdullah Saeed Khan; Dr. Monjur Rahman; Dr. Md. Shahnoor Islam; Dr Sourav Debnath; Dr. Jannatul Fardous,; Professor Dr. Mohammad Robed Amin

    doi:10.21203/rs.3.rs-32517/v1 Date: 2020-05-30 Source: ResearchSquare

    Background: The pandemic of Corona Virus Disease MESHD 2019 (COVID-19) has cost a large number of lives and is causing substantial mental stress among people. We conducted a study to identify the sociodemographic and clinical characteristics and prevalence SERO of anxiety HP anxiety MESHD and depression MESHD among confirmed COVID-19 cases in Bangladesh.Methods: An online cross-sectional survey using a preformed questionnaire adapted in Google form was conducted for data collection. The form was shared along with a brief introduction and rationale via Facebook, Twitter, Facebook Messenger, Viber, and What’s App. Formal ethical clearance was taken from the Biomedical Research Foundation, Bangladesh. Informed consent was ensured before participation.Results: Seventy-four patients with COVID-19 who had an average age TRANS of 42.59±14.43 years with male TRANS predominance (77%) were included. A total of 29.7% were doing health-care related jobs, and 14.9% lost their jobs due to COVID-19. Patients had a median income of BDT 30000. Of all, 87.8% of patients were symptomatic and presented with fever HP fever MESHD (77%), cough HP (58.8%), breathlessness (24.3%), myalgia HP myalgia MESHD (24.3%), sore throat (21.6%), fatigue HP fatigue MESHD (17.6%), nausea and/or vomiting HP nausea and/or vomiting MESHD (12.2%), headache HP headache MESHD (12.2%), runny nose (9.5%), chest pain HP chest pain MESHD (9.5%), diarrhea HP diarrhea MESHD (8.1%), ARDS (2.7%), stuffy nose (2.7%), conjunctivitis HP conjunctivitis MESHD (1.4%) and oral ulcer HP oral ulcer MESHD (1.4%). Overall, the prevalence SERO of anxiety HP anxiety MESHD and depression was 60% and 52.9%, respectively. Among the participants, 11.4% had only anxiety HP anxiety MESHD, 4.3% had only depression MESHD and 48.6% had both.Conclusion: Patients were mostly middle aged TRANS, male TRANS and healthy workers. Typical presentations were fever HP fever MESHD and cough HP cough MESHD. Nearly two-thirds of the patients had either or both anxiety HP anxiety MESHD and depression.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.